Literature DB >> 28840443

Preoperative Carbohydrate Antigen 19-9: Its Neglected Role in Alpha-Fetoprotein-Negative Hepatocellular Carcinoma Patients.

Liang-He Lu1,2,3, Yong-Fa Zhang4,5,6, Wei Wei1,2,3, Ming Shi1,2,3, Rong-Ping Guo7,8,9.   

Abstract

PURPOSE: The study aimed to investigate the prognostic role of the preoperative carbohydrate antigen 19-9 (CA19-9) level in alpha-fetoprotein (AFP)-negative (AFP < 25 ng/ml) hepatocellular carcinoma (HCC) patients.
METHODS: From December 2004 to December 2013, 750 patients diagnosed with AFP-negative HCC following curative resection were enrolled. Both univariate and multivariate analyses were performed to clarify the prognostic factors for overall survival (OS) and disease-free survival (DFS).
RESULTS: The optimal cutoff point for preoperative CA19-9 was 32.6 U/ml, and the value of the area under the curve was 0.640. The 1-, 3-, and 5-year OS rates were 88.4, 72.2, and 57.0%, respectively, for the CA19-9 > 32.6 U/ml group and 97.0, 83.3, and 79.9%, respectively, for the CA19-9 ≤ 32.6 U/ml group (P < 0.001). The 1-, 3-, and 5-year DFS rates were 71.8, 47.7, and 34.8%, respectively, for the CA19-9 > 32.6 U/ml group and 80.8, 63.6, and 55.5%, respectively, for the CA19-9 ≤ 32.6 U/ml group (P < 0.001). The multivariate analysis showed that CA19-9 > 32.6 U/ml was one of the most significant unfavorable predictors of OS and DFS (P < 0.001 for both).
CONCLUSIONS: Preoperative CA19-9 > 32.6 U/ml is a predictor of dismal prognosis and can be employed as a prognostic marker for patient selection in AFP-negative HCC management.

Entities:  

Keywords:  AFP-negative; Carbohydrate antigen 19-9; Hepatocellular carcinoma; Prognosis; Resection

Mesh:

Substances:

Year:  2017        PMID: 28840443     DOI: 10.1007/s11605-017-3528-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  34 in total

1.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

2.  Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma.

Authors:  Jinyan Zhang; Tao Huang; Fan Zhang; Junming Xu; Guoqing Chen; Xiaoliang Wang; Li Huang; Zhihai Peng
Journal:  Tumour Biol       Date:  2015-03-19

3.  Level of α-fetoprotein predicts mortality among patients with hepatitis C-related hepatocellular carcinoma.

Authors:  Gia L Tyson; Zhigang Duan; Jennifer R Kramer; Jessica A Davila; Peter A Richardson; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2011-08-04       Impact factor: 11.382

4.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

5.  Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels.

Authors:  P Tangkijvanich; N Anukulkarnkusol; P Suwangool; S Lertmaharit; O Hanvivatvong; P Kullavanijaya; Y Poovorawan
Journal:  J Clin Gastroenterol       Date:  2000-12       Impact factor: 3.062

Review 6.  Management of combined hepatocellular and cholangiocarcinoma.

Authors:  W T Kassahun; J Hauss
Journal:  Int J Clin Pract       Date:  2008-02-13       Impact factor: 2.503

7.  Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes.

Authors:  Shimul A Shah; Sean P Cleary; Alice C Wei; Ilun Yang; Bryce R Taylor; Alan W Hemming; Bernard Langer; David R Grant; Paul D Greig; Steven Gallinger
Journal:  Surgery       Date:  2006-11-01       Impact factor: 3.982

8.  Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.

Authors:  Christine C Hsu; Abhishek Goyal; Alina Iuga; Saravanan Krishnamoorthy; Valerie Lee; Elizabeth C Verna; Shuang Wang; Fei-Na Chen; Rosa Rodriguez; Jean Emond; Paul Berk; Jay Lefkowitch; Lorna Dove; Robert S Brown; Abby B Siegel
Journal:  Clin Transl Gastroenterol       Date:  2015-02-05       Impact factor: 4.488

9.  Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making.

Authors:  Yong-Fa Zhang; Jie Zhou; Wei Wei; Ru-Hai Zou; Min-Shan Chen; Wan Yee Lau; Ming Shi; Rong-Ping Guo
Journal:  Br J Cancer       Date:  2016-10-04       Impact factor: 7.640

10.  Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.

Authors:  Ping Wan; Jianjun Zhang; Xidai Long; Qigen Li; Ning Xu; Ming Zhang; Xiaosong Chen; Longzhi Han; Qiang Xia
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-05       Impact factor: 2.566

View more
  5 in total

1.  Prognostic significance of combined α-fetoprotein and CA19-9 for hepatocellular carcinoma after hepatectomy.

Authors:  Jie Zhang; Shang Dong Qin; Yan Li; Fei Lu; Wen Feng Gong; Jian Hong Zhong; Liang Ma; Jing Fei Zhao; Guo Hua Zhan; Peng Zhan Li; Bin Song; Bang De Xiang
Journal:  World J Surg Oncol       Date:  2022-10-19       Impact factor: 3.253

2.  Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC.

Authors:  Zijing Liu; Youwei Pu; Yixi Bao; Song He
Journal:  Int J Gen Med       Date:  2021-08-10

Review 3.  Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.

Authors:  Tsinrong Lee; Thomas Zheng Jie Teng; Vishal G Shelat
Journal:  World J Gastrointest Surg       Date:  2020-12-27

4.  Novel Value of Preoperative Gamma-Glutamyltransferase Levels in the Prognosis of AFP-Negative Hepatocellular Carcinoma.

Authors:  Liang-He Lu; Anna Kan; Yi-Hong Ling; Shao-Hua Li; Rong-Ping Guo
Journal:  Dis Markers       Date:  2020-07-10       Impact factor: 3.434

5.  Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection.

Authors:  Kongying Lin; Qizhen Huang; Jianxing Zeng; Zongren Ding; Lei Wang; Zhenwei Chen; Pengfei Guo; Yongyi Zeng; Weiping Zhou; Jingfeng Liu
Journal:  Dig Dis Sci       Date:  2021-03-16       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.